ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement

References

• Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471–486.
   PubMed Web of Science ®Google Scholar
• Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004;5:554–565.
   PubMed Web of Science ®Google Scholar
• Parkinson-Lawrence EJ, Shandala T, Prodoehl M, et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology. 2010;25:102–115.
   PubMed Web of Science ®Google Scholar
• Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. Forthcoming. [cited 2017 May 11]. doi: 10.1016/j.addr.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Kirkegaard T. Emerging therapies and therapeutic concepts for lysosomal storage diseases. Expert Opin Orphan Drugs. 2013;1:385–404.
   Web of Science ®Google Scholar
• Muro S. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. Drug Deliv Transl Res. 2012;2:169–186.
   PubMed Web of Science ®Google Scholar
• Hsu J, Northrup L, Bhowmick T, et al. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine. 2012;8:731–739.
   PubMed Web of Science ®Google Scholar
• Hsu J, Serrano D, Bhowmick T, et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Rel. 2011;149:323–331.
   PubMed Web of Science ®Google Scholar
• Garnacho C, Dhami R, Simone E, et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther. 2008;325:400–408.
   PubMed Web of Science ®Google Scholar
• Muro S. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. In: Aird W, editor. Endothelial biomedicine. New York (NY): Cambridge University Press. 2007. Chapter 117. p. 1058–1070.
   Google Scholar
• Muro S, Wiewrodt R, Thomas A, et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci. 2003;116:1599–1609.
   PubMed Web of Science ®Google Scholar
• Serrano D, Bhowmick T, Chadha R, et al. Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler Thromb Vasc Biol. 2012;32:1178–1185.
   PubMed Web of Science ®Google Scholar
• Rappaport J, Manthe R, Solomon M, et al. A comparative study on the alterations of endocytic pathways in multiple lysosomal storage disorders. Mol Pharm. 2016;13:357–368.
   PubMed Web of Science ®Google Scholar
• Serrano D, Muro S. Endothelial cell adhesion molecules and drug delivery applications. In: Aranda-Espinoza H, editor. Mechanobiology of the endothelium. Boca Raton (FL): CRC Press; 2014. Chapter 9. p. 185–226.
   Google Scholar
• Muro S. A DNA device that mediates selective endosomal escape and intracellular delivery of drugs and biological. Adv Funct Mater. 2014;24:2899–2906.
   PubMed Web of Science ®Google Scholar
• Choi KS, Kim SH, Cai QY, et al. Inflammation-specific T1 imaging using anti-intercellular adhesion molecule 1 antibody-conjugated gadolinium diethylenetriaminepentaacetic acid. Mol Imaging. 2007;6:75–84.
   PubMed Web of Science ®Google Scholar
• Weller GE, Villanueva FS, Tom EM, et al. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng. 2005;92:780–788.
   PubMed Web of Science ®Google Scholar
• Greineder CF, Chacko AM, Zaytsev S, et al. Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor. PLoS One. 2013;8:e80110.
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Storm G, van Bloois L, et al. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta. 1999;1419:353–363.
   PubMed Web of Science ®Google Scholar
• Zhang N, Chittasupho C, Duangrat C, et al. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjugate Chem. 2008;19:145–152.
   PubMed Web of Science ®Google Scholar
• Park S, Kang S, Veach AJ, et al. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials. 2010;31:7766–7775.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Gupta V, Zern BJ, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano. 2013;7:11129–11137.
   PubMed Web of Science ®Google Scholar
• Shuvaev VV, Ilies MA, Simone E, et al. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano. 2011;5:6991–6999.
   PubMed Web of Science ®Google Scholar
• Muro S, Schuchman E, Muzykantov V. Lysosomal enzyme delivery by ICAM-1 targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther. 2006;13:135–141.
   PubMed Web of Science ®Google Scholar
• Hsu J, Bhowmick T, Burks S, et al. Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers. J Biomed Nanotechnol. 2013;10:345–354.
   Web of Science ®Google Scholar
• Muro S, Dziubla T, Qiu W, et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther. 2006;317:1161–1169.
   PubMed Web of Science ®Google Scholar
• Garnacho C, Albelda S, Muzykantov V, et al. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release. 2008;130:226–233.
   PubMed Web of Science ®Google Scholar
• Han J, Shuvaev VV, Davies PF, et al. Flow shear stress differentially regulates endothelial uptake of nanocarriers targeted to distinct epitopes of PECAM-1. J Control Release. 2015;28:39–47.
   Web of Science ®Google Scholar
• Altieri DC, Duperray A, Plescia J, et al. Structural recognition of a novel fibrinogen gamma chain sequence (117–133) by intercellular adhesion molecule-1 mediates leukocyte-endothelium interaction. J Biol Chem. 1995;270:696–699.
   PubMed Web of Science ®Google Scholar
• Ghaffarian R, Pérez-Herrero E, Oh H, et al. Chitosan-alginate microcapsules provide gastric protection and intestinal release of ICAM-1-targeting nanocarriers, enabling GI targeting in vivo. Adv Funct Mater. 2016;26:3382–3393.
   PubMed Web of Science ®Google Scholar
• Serrano D, Manthe RL, Paul E, et al. How carrier size and valency modulate receptor-mediated signaling: understanding the link between binding and endocytosis of ICAM-1-targeted carriers. Biomacromolecules. 2016;17:3127–3137.
   PubMed Web of Science ®Google Scholar
• Garnacho C, Serrano D, Muro S. A fibrinogen-derived peptide provides ICAM-1-specific vascular targeting and intra-endothelial transport of polymers nanocarriers in cell cultures and mice. J Pharm Exp Ther. 2012;340:638–647.
   PubMed Web of Science ®Google Scholar
• Muro S, Cui X, Gajewski CM, et al. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Phys-Cell Physiol. 2003;285:C1339–13347.
   PubMed Web of Science ®Google Scholar
• Muro S, Garnacho C, Champion J, et al. Controlled endothelial targeting and intracellular delivery of therapeutics by modulating size and shape of ICAM-1-targeted carriers. Mol Ther. 2008;16:1450–1458.
   PubMed Web of Science ®Google Scholar
• Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis. 2007;30:654–663.
   PubMed Web of Science ®Google Scholar
• Rappaport J, Garnacho C, Muro S. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Mol Pharmaceutics. 2014;11:2887–2895.
   PubMed Web of Science ®Google Scholar
• Dhami R, Schuchman EH. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem. 2004;279:1526–1532.
   PubMed Web of Science ®Google Scholar
• Belizaire AK, Tchistiakova L, St-Pierre Y, et al. Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells. Biochem Biophys Res Commun. 2003;309:625–630.
   PubMed Web of Science ®Google Scholar
• Anderson ME, Siahaan TJ. Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharm Res. 2003;20:1523–1532.
   PubMed Web of Science ®Google Scholar
• Sillerud LO, Burks EJ, Brown WM, et al. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution. J Pept Res. 2004;64:127–140.
   PubMedGoogle Scholar
• Welply JK, Steininger CN, Caparon M, et al. A peptide isolated by phage display binds to ICAM-1 and inhibits binding to LFA-1. Proteins. 1996;26:262–270.
   PubMed Web of Science ®Google Scholar
• Khodabandehlou K, Masehi-Lano JJ, Poon C, et al. Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis. Exp Biol Med (Maywood). 2017;242:799–812.
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Xie SX, Baoum A, et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci. 2009;37:141–150.
   PubMed Web of Science ®Google Scholar
• Languino LR, Plescia J, Duperray A, et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 1993;73:1423–1434.
   PubMed Web of Science ®Google Scholar
• Manthe R, Muro S. ICAM-1-targeted nanocarriers attenuate endothelial release of sICAM-1, and inflammatory regulator. Bioeng Transl Med. 2017;2:109--119.
   PubMed Web of Science ®Google Scholar
• Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw. 2004;15:91–98.
   PubMed Web of Science ®Google Scholar